Brazil approves country’s first biosimilar


The National Health Surveillance Agency in Brazil, known as ANVISA, has approved Remsima as the country’s first biosimilar. Hospira, in a partnership with Celltrion, is producing the drug, though Hospira will handle the marketing and distribution. Remsima, which is also known as infliximab, is a monoclonal antibody and is already sold in 26 European countries as well as Canada. The drug treats rheumatoid arthritis and other inflammatory conditions.


Read the source article at Pharmacy Choice

About the Author

Related Posts

Leave a Reply